ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been given a consensus rating of “Buy” by the six ratings firms that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.75.
A number of equities analysts recently issued reports on SPRY shares. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Monday. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $18.00 to $22.00 in a research note on Tuesday, August 13th. Finally, Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, August 12th.
View Our Latest Stock Analysis on SPRY
Insider Transactions at ARS Pharmaceuticals
Institutional Trading of ARS Pharmaceuticals
Several hedge funds have recently modified their holdings of SPRY. The Manufacturers Life Insurance Company purchased a new position in shares of ARS Pharmaceuticals in the 2nd quarter worth approximately $180,000. Renaissance Technologies LLC boosted its stake in ARS Pharmaceuticals by 884.9% in the second quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock valued at $1,056,000 after acquiring an additional 111,500 shares in the last quarter. J.W. Cole Advisors Inc. grew its holdings in ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after purchasing an additional 1,500 shares during the last quarter. American Century Companies Inc. increased its position in shares of ARS Pharmaceuticals by 20.7% during the second quarter. American Century Companies Inc. now owns 97,803 shares of the company’s stock worth $832,000 after purchasing an additional 16,761 shares in the last quarter. Finally, ClariVest Asset Management LLC increased its position in shares of ARS Pharmaceuticals by 5.4% during the second quarter. ClariVest Asset Management LLC now owns 287,596 shares of the company’s stock worth $2,447,000 after purchasing an additional 14,640 shares in the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.
ARS Pharmaceuticals Trading Up 7.7 %
SPRY stock opened at $14.05 on Friday. The stock has a market cap of $1.36 billion, a PE ratio of -27.21 and a beta of 0.90. ARS Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $16.50. The company has a 50-day moving average price of $11.81 and a 200 day moving average price of $9.94.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $2.00 million. Sell-side analysts forecast that ARS Pharmaceuticals will post -0.66 EPS for the current year.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
- Five stocks we like better than ARS Pharmaceuticals
- How to Calculate Retirement Income: MarketBeat’s Calculator
- How Much Can You Make in Stocks in One Month?
- Why is the Ex-Dividend Date Significant to Investors?
- This Is the Top Large-Cap Stock Insiders Are Buying
- What Are Dividend Achievers? An Introduction
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.